Maxim Group Assigns a Buy Rating on OncoSec Medical

By Ryan Adsit

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to OncoSec Medical (NASDAQ: ONCS), with a price target of $5. The company’s shares opened today at $1.97.

McCarthy commented:

“Oncosec announced positive data from a pilot biomarker study (OMS-1140) evaluating TAVO (DNA-based IL-12) in metastatic triple negative breast cancer (TNBC) demonstrating that a single cycle of IL-12 increases tumor immunogenicity, turning “cold” tumors “hot”.”

According to, McCarthy is a 2-star analyst with an average return of 0.5% and a 37.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Stellar Biotechnologies, Inc., and ImmunoCellular Therapeutics.

OncoSec Medical has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

Based on OncoSec Medical’s latest earnings report for the quarter ending October 31, the company posted quarterly revenue of $0 and GAAP net loss of $5.9 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $5.6 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications. The company was founded by Avtar S. Dhillon, Punit S.